Evotec sees a 13.3% stock rise amid reports of Triton Partners eyeing a potential buyout after acquiring a 9.99% stake in the ...
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics, Bloomberg News reported on Thursday. Halozyme has recently expressed interest in acquiring Evotec at ...
Evotec listed three investors with stakes of 5% or greater in its 2023 annual report. At that time, T. Rowe Price was the ...
Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...
Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.
Any significant move would also need support from Evotec’s other major shareholders — Novo Holdings A/S, the parent company of drugmaker Novo Nordisk A/S, as well as Abu Dhabi sovereign fund ...
Analyst Brendan Smith of TD Cowen maintained a Buy rating on Evotec AG (EVO – Research Report), with a price target of $10.00. Brendan ...
Evotec agreed to sell its chemical API production facility ... Canadian drugmaker Apotex hired banks to prepare for its IPO ...
Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market ...
Evotec Ag (Adr) ( (EVO) ) has released its Q3 earnings. Here is a breakdown of the information Evotec Ag (Adr) presented to its investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback